Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | STS | P08842 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6399210 | 0.85 | MCL1 (0.48) | STSALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL6400376 | 0.83 | MAPK1 (0.56) | MAPK1STSALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL29055579 | 0.83 | STS (0.63) | MAPK1STSALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL6399653 | 0.81 | STS (0.41) | MAPK1STSSMN1; SMN2NPC1HTT | |
| SCHEMBL6399655 | 0.81 | STS (0.41) | MAPK1STSSMN1; SMN2NPC1HTT | |
| SCHEMBL6399650 | 0.81 | STS (0.41) | MAPK1STSSMN1; SMN2NPC1HTT | |
| SCHEMBL9541270 | 0.80 | STS (0.59) | MAPK1STSALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL4544921 | 0.80 | CA1 (0.60) | STSSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL6398961 | 0.77 | MAPK1 (0.47) | MAPK1STSALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL6400288 | 0.77 | MAPK1 (0.49) | MAPK1STSALDH1A1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949585-B2 | Cyclooctanone derivatives and cyclodecanone derivative, and use thereof | EISAI CO., LTD. (JP) | 2005-09-27 | — | — | US | disclosed |
| US-20040082805-A1 | Cyclooctanone derivatives and cyclodecanone derivative, and use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1375465-A9 | CYCLOOCTANONE DERIVATIVE AND CYCLODECANONE DERIVATIVE, AND USE THEREOF | Eisai Co., Ltd. (JP) | 2004-04-14 | — | — | EP | disclosed |
| EP-1375479-A1 | PYRROLIDINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | Eisai Co., Ltd. (JP) | 2004-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082805-A1 | Cyclooctanone derivatives and cyclodecanone derivative, and use thereof | CCR1, CCL2, CCR5 | MAPK1 1166/4885STS 2310/4885ALDH1A1 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.